Adalimumab for endoscopic and histopathological mucosal healing in paediatric patients with moderate to severe Crohn’s disease

Adalimumab for endoscopic and histopathological mucosal healing in paediatric patients with moderate to severe Crohn’s disease

Introduction : Deep remission, defined as clinical remission with mucosal healing (MH), with anti-tumor necrosis factor (TNF)-α agents is a new target for therapy in Crohn’s disease (CD). Provided that the efficacy of infliximab (IFX) for induction of MH in CD has been demonstrated, there are much l...

Full description

Bibliographic Details
Main Authors: Edyta Szymanska, Maciej Dadalski, Wieslawa Grajkowska, Sylwia Szymanska, Maciej Pronicki, Jaroslaw Kierkus
Format: Article
Language:English
Published: Termedia Publishing House 2016-12-01
Series:Gastroenterology Review
Subjects:
adalimumab
deep remission
mucosal healing
Crohn’s disease
Online Access:https://www.termedia.pl/Adalimumab-for-endoscopic-and-histopathological-mucosal-healing-in-paediatric-patients-with-moderate-to-severe-Crohn-s-disease,41,28947,1,1.html

Internet

https://www.termedia.pl/Adalimumab-for-endoscopic-and-histopathological-mucosal-healing-in-paediatric-patients-with-moderate-to-severe-Crohn-s-disease,41,28947,1,1.html

Similar Items